Real life adherence of chronic hepatitis B patients to entecavir treatment

Lotte G van Vlerken; Pauline Arends; Faydra I Lieveld; Joop E Arends; Willem Pieter Brouwer; Peter D Siersema; Harry L Janssen; KJ van Erpecum

doi:10.1016/j.dld.2015.03.024

Real life adherence of chronic hepatitis B patients to entecavir treatment

Lotte G van Vlerken, Pauline Arends, Faydra I Lieveld, Joop E Arends, Willem Pieter Brouwer, Peter D Siersema, Harry L Janssen, KJ van Erpecum

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Real-life prospective data on adherence to nucleos(t)ide analogues in chronic hepatitis B patients are scarce.

AIMS: We investigated adherence to entecavir in relation to virological response.

METHODS: In this prospective study, we provided 100 consecutive chronic hepatitis B patients with a medication dispenser that monitored entecavir intake during 16 weeks therapy. Hepatitis B virus (HBV) DNA was measured at baseline and after 16 weeks. Beliefs about medicines were evaluated using a questionnaire.

RESULTS: Adherence over 16 weeks averaged 85 ± 17%, with 70% of patients exhibiting good (i.e. ≥ 80%) adherence. Patients with poor (i.e. <80%) adherence were significantly younger (p=0.01), with more often indifferent attitudes towards entecavir (p=0.03) Viral breakthrough did not occur during the study. Adherence in patients with HBV DNA after 16 weeks > 20 IU/mL (n=18) and ≤ 20 IU/mL (n=81) averaged 83% and 91% respectively (p=0.19). In multivariate analysis, adherence was not a significant predictor of HBV DNA negativity (adjusted OR 1.02; p=0.34), after adjustment for duration of entecavir treatment (p<0.001) and HBe-status (p=0.001).

CONCLUSIONS: 70% of chronic hepatitis B patients exhibited good adherence to entecavir, with younger age and an indifferent attitude being risk factors for poor adherence. Poor adherence was not an independent predictor of virological response.

Original language	English
Pages (from-to)	577-83
Number of pages	7
Journal	Digestive and liver disease
Volume	47
Issue number	7
DOIs	https://doi.org/10.1016/j.dld.2015.03.024
Publication status	Published - Jul 2015

Keywords

Beliefs about medicine
Compliance
Hepatitis B virus
Real-time medication monitoring

Access to Document

10.1016/j.dld.2015.03.024

Cite this

@article{5ecbf035b540484c996955d9b068ba5f,

title = "Real life adherence of chronic hepatitis B patients to entecavir treatment",

abstract = "BACKGROUND: Real-life prospective data on adherence to nucleos(t)ide analogues in chronic hepatitis B patients are scarce.AIMS: We investigated adherence to entecavir in relation to virological response.METHODS: In this prospective study, we provided 100 consecutive chronic hepatitis B patients with a medication dispenser that monitored entecavir intake during 16 weeks therapy. Hepatitis B virus (HBV) DNA was measured at baseline and after 16 weeks. Beliefs about medicines were evaluated using a questionnaire.RESULTS: Adherence over 16 weeks averaged 85 ± 17\%, with 70\% of patients exhibiting good (i.e. ≥ 80\%) adherence. Patients with poor (i.e. <80\%) adherence were significantly younger (p=0.01), with more often indifferent attitudes towards entecavir (p=0.03) Viral breakthrough did not occur during the study. Adherence in patients with HBV DNA after 16 weeks > 20 IU/mL (n=18) and ≤ 20 IU/mL (n=81) averaged 83\% and 91\% respectively (p=0.19). In multivariate analysis, adherence was not a significant predictor of HBV DNA negativity (adjusted OR 1.02; p=0.34), after adjustment for duration of entecavir treatment (p<0.001) and HBe-status (p=0.001).CONCLUSIONS: 70\% of chronic hepatitis B patients exhibited good adherence to entecavir, with younger age and an indifferent attitude being risk factors for poor adherence. Poor adherence was not an independent predictor of virological response.",

keywords = "Beliefs about medicine, Compliance, Hepatitis B virus, Real-time medication monitoring",

author = "\{van Vlerken\}, \{Lotte G\} and Pauline Arends and Lieveld, \{Faydra I\} and Arends, \{Joop E\} and Brouwer, \{Willem Pieter\} and Siersema, \{Peter D\} and Janssen, \{Harry L\} and \{van Erpecum\}, KJ",

year = "2015",

month = jul,

doi = "10.1016/j.dld.2015.03.024",

language = "English",

volume = "47",

pages = "577--83",

journal = "Digestive and liver disease",

issn = "1590-8658",

publisher = "Elsevier",

number = "7",

}

TY - JOUR

T1 - Real life adherence of chronic hepatitis B patients to entecavir treatment

AU - van Vlerken, Lotte G

AU - Arends, Pauline

AU - Lieveld, Faydra I

AU - Arends, Joop E

AU - Brouwer, Willem Pieter

AU - Siersema, Peter D

AU - Janssen, Harry L

AU - van Erpecum, KJ

PY - 2015/7

Y1 - 2015/7

N2 - BACKGROUND: Real-life prospective data on adherence to nucleos(t)ide analogues in chronic hepatitis B patients are scarce.AIMS: We investigated adherence to entecavir in relation to virological response.METHODS: In this prospective study, we provided 100 consecutive chronic hepatitis B patients with a medication dispenser that monitored entecavir intake during 16 weeks therapy. Hepatitis B virus (HBV) DNA was measured at baseline and after 16 weeks. Beliefs about medicines were evaluated using a questionnaire.RESULTS: Adherence over 16 weeks averaged 85 ± 17%, with 70% of patients exhibiting good (i.e. ≥ 80%) adherence. Patients with poor (i.e. <80%) adherence were significantly younger (p=0.01), with more often indifferent attitudes towards entecavir (p=0.03) Viral breakthrough did not occur during the study. Adherence in patients with HBV DNA after 16 weeks > 20 IU/mL (n=18) and ≤ 20 IU/mL (n=81) averaged 83% and 91% respectively (p=0.19). In multivariate analysis, adherence was not a significant predictor of HBV DNA negativity (adjusted OR 1.02; p=0.34), after adjustment for duration of entecavir treatment (p<0.001) and HBe-status (p=0.001).CONCLUSIONS: 70% of chronic hepatitis B patients exhibited good adherence to entecavir, with younger age and an indifferent attitude being risk factors for poor adherence. Poor adherence was not an independent predictor of virological response.

AB - BACKGROUND: Real-life prospective data on adherence to nucleos(t)ide analogues in chronic hepatitis B patients are scarce.AIMS: We investigated adherence to entecavir in relation to virological response.METHODS: In this prospective study, we provided 100 consecutive chronic hepatitis B patients with a medication dispenser that monitored entecavir intake during 16 weeks therapy. Hepatitis B virus (HBV) DNA was measured at baseline and after 16 weeks. Beliefs about medicines were evaluated using a questionnaire.RESULTS: Adherence over 16 weeks averaged 85 ± 17%, with 70% of patients exhibiting good (i.e. ≥ 80%) adherence. Patients with poor (i.e. <80%) adherence were significantly younger (p=0.01), with more often indifferent attitudes towards entecavir (p=0.03) Viral breakthrough did not occur during the study. Adherence in patients with HBV DNA after 16 weeks > 20 IU/mL (n=18) and ≤ 20 IU/mL (n=81) averaged 83% and 91% respectively (p=0.19). In multivariate analysis, adherence was not a significant predictor of HBV DNA negativity (adjusted OR 1.02; p=0.34), after adjustment for duration of entecavir treatment (p<0.001) and HBe-status (p=0.001).CONCLUSIONS: 70% of chronic hepatitis B patients exhibited good adherence to entecavir, with younger age and an indifferent attitude being risk factors for poor adherence. Poor adherence was not an independent predictor of virological response.

KW - Beliefs about medicine

KW - Compliance

KW - Hepatitis B virus

KW - Real-time medication monitoring

U2 - 10.1016/j.dld.2015.03.024

DO - 10.1016/j.dld.2015.03.024

M3 - Article

C2 - 25936691

SN - 1590-8658

VL - 47

SP - 577

EP - 583

JO - Digestive and liver disease

JF - Digestive and liver disease

IS - 7

ER -

Real life adherence of chronic hepatitis B patients to entecavir treatment

Abstract

Keywords

Access to Document

Fingerprint

Cite this